Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, other-events
TL;DR
Telomir Pharma filed an 8-K for 'Other Events' on Nov 20, but details are scarce.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or new agreements. The company is incorporated in Florida and its principal executive offices are located in Miami.
Why It Matters
This 8-K filing indicates a material event has occurred for Telomir Pharmaceuticals, Inc., requiring disclosure to investors. However, the lack of specific details leaves investors uncertain about the nature and impact of this event.
Risk Assessment
Risk Level: medium — The filing is an 8-K, indicating a material event, but the lack of specific details about the 'Other Events' creates uncertainty and potential risk for investors.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
- 33131 (location) — Principal Executive Offices Zip Code
- (813) 864-2558 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Telomir Pharmaceuticals, Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 20, 2024.
What is the state of incorporation for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
Where are the principal executive offices of Telomir Pharmaceuticals, Inc. located?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131.
What is the telephone number for Telomir Pharmaceuticals, Inc.?
The telephone number is (813) 864-2558.
Filing Stats: 1,077 words · 4 min read · ~4 pages · Grade level 16.7 · Accepted 2024-11-20 16:15:35
Filing Documents
- form8-k.htm (8-K) — 47KB
- 0001493152-24-046982.txt ( ) — 222KB
- telo-20241120.xsd (EX-101.SCH) — 3KB
- telo-20241120_lab.xml (EX-101.LAB) — 33KB
- telo-20241120_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: November 20, 2024 By: /s/ Erez Aminov Erez Aminov Chief Executive Officer